Guggenheim Reiterates Buy on Bristol-Myers Squibb, Maintains $72 Price Target

Benzinga Newsdesk www.benzinga.com Neutral 90.4%

Neg 0% Neu 90.4% Pos 0%

Guggenheim analyst Seamus Fernandez reiterates Bristol-Myers Squibb (NYSE:BMY) with a Buy and maintains $72 price target.